Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• Male or female patients aged 40 years or over with moderate to severe chronic obstructive pulmonary disease (COPD) plus~* 20 pack-year smoking history~* Signed informed consent~* Post-bronchodilator forced expiratory volume in 1 second )FEV1) ≥ 30% and \< 80% predicted FEV1/FVC (forced vital capacity) \< 70%~Exclusion Criteria include:~* History of asthma~* Prior exposure to indacaterol~* Active cancer or history of cancer~* Patients with concomitant pulmonary disease~* Patients with diabetes Type I or uncontrolled diabetes Type II~* Patients with a history of long QT syndrome or whose QTc interval (Bazett's) measured at screening or randomization is prolonged~* Patients unable to successfully use a dry-powder inhaler device or perform spirometry measurements~Other protocol-defined inclusion/exclusion criteria applied to the study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indacaterol 150 μg (Type: EXPERIMENTAL): Patients inhaled indacaterol 150 μg once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
- Placebo to indacaterol (Type: PLACEBO_COMPARATOR): Patients inhaled placebo to indacaterol once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).